-
Net Sales are expected to decrease by 6.5 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs 1,363 crore, according to ICICI Direct.
-
Net Sales are expected to decrease by 5.6 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs 1,266 crore, according to KRChoksey.
-
Net Sales are expected to decrease by 4 percent Y-o-Y (up 6 percent Q-o-Q) to Rs 1,287.6 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 17.7 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs. 1,422.8 crore, according to ICICI Direct.
-
-
The company reported 33.8 percent jump in its Q3FY20 net profit to Rs 227.31 crore, EBITDA up 32.4 percent at Rs 325.46 crore
-
Earnings downgrade continued in the September quarter but there were no fresh negatives in terms of outlook in management commentaries.
-
Net Sales are expected to increase by 21.4 percent Y-o-Y (down 9.5 percent Q-o-Q) to Rs. 1019.5 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 18.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 940 crore, according to HDFC Securities.
-
Net Sales are expected to increase by 20.7 percent Y-o-Y (up 10.4 percent Q-o-Q) to Rs. 952.3 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 21.2 percent Y-o-Y (up 7 percent Q-o-Q) to Rs. 898.8 crore, according to KR Choksey.
-
Net Sales are expected to increase by 6.3 percent Y-o-Y (down 6.6 percent Q-o-Q) to Rs. 780 crore, according to HDFC Securities.
-
Net Sales are expected to decrease by 6.86 percent Q-o-Q (down 6.29 percent Y-o-Y) to Rs 689.5 crore, according to KR Choksey. Alembic Pharma to report net profit at 86.3 crore down 16.70% year-on-year.
-
Net Sales are expected to increase by 2.6 percent Q-o-Q (up 26.3 percent Y-o-Y) to Rs 791.1 crore, according to ICICI Securities. Alembic Pharma to report net profit at 71.3 crore up 66.6% quarter-on-quarter.
-
Alembic Pharmaceuticals is expected to show massive degrowth in third quarter earnings due to unfavourable base in year-ago quarter. Profit is likely to fall 60 percent year-on-year to Rs 107 crore and revenue may slip 14 percent to Rs 794 crore in Q3, according to average of estimates of analysts polled by CNBC-TV18.
-
Net Sales are expected to decrease by 9.5 percent Q-o-Q (down 14.2 percent Y-o-Y) to Rs 790 crore, according to HDFC Securities.
-
Net Sales are expected to decrease by 12.6 percent Q-o-Q (down 17.3 percent Y-o-Y) to Rs 762.3 crore, according to ICICI Securities.
-
Net Sales are expected to decrease by 18.4 percent Q-o-Q (down 22.1 percent Y-o-Y) to Rs 717.4 crore, according to KR Choksey.
-
Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.
-
In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.
-
The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.
-
In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.
-
Alembic Pharma is hopeful to increase operating margin by 100-120 basis points in current financial year on the back of strong growth in international and domestic generic business.
-
Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.
-
Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.
